Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 397 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens... January 9, 2023 EMA Recommends Extending Indications for Trastuzumab Deruxtecan to Include Treatment of... October 12, 2023 Minimizing Time Between Diagnosis and End of Treatment Improves Breast Cancer... July 5, 2021 2021/22 in review: Charity looks to the future with ambitious new... July 21, 2022 Load more HOT NEWS Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer Survival According Circulating Tumour DNA Status in the Study of Adjuvant... Combination of Azacitidine and Venetoclax in Previously Untreated AML Woman Perfectly Breaks Down Grief Using ‘Ball In The Box’ Analogy...
